Goosebumps posted a link to an article on GripRoom
Post# of 148119
(Total Views: 790)
Posted On: 12/05/2021 10:03:05 AM
Re: Goosebumps #111687
Goosebumps posted a link to an article on GripRoom which noted that the FDA said they were going to speed up approval of new Covid vaccines and treatments. I was not familiar with GripRoom, so I looked at some of the other articles. There is an article about Pfizer's Covid pill not being as great as they say. Some have posted on other boards that it is too late for CYDY to get Covid approval and they should just go after Long Haulers. After reading this article, that assumption is probably not true.
You can read the article at this link. I have posted most of it below.
https://www.griproom.com/fun/pfizers-covid-pi...yre-saying
After stating on November 2nd that trial results for their Covid-19 pill might not be out until 2022, Pfizer released results this morning (three days later) touting an 89% reduction in hospitalization.
Merck’s Covid-19 pill (50% reduction in hospitalization with possibly mutagenic side-effects) was an obvious cash grab. Their sales team was scrambling to dump the product and sign deals before better oral treatments were announced. And they would have gotten away with it to, if it wasn’t for that meddling Pfizer. Atea/Roche’s drug flopped in trials, and Pfizer said their data would be delayed by months. This would have given Merck a tiny window to unload their drug. Just yesterday the UK approved molnupiravir, although they’re now probably regretting it.
89% vs 50% sounds like it’s a lot better, right? But here’s the thing. Merck’s trial was a lot different. Pfizer had 45% US patients. Merck only 7%. (We can expect the healthcare given to US patients in a big pharma study to be better than the healthcare given in India.) While not a deal-breaker, this next bit of data is.
Covid-19 disproportionately affects certain groups. Like people with diabetes, hypertension, asthma, chronic lung disease, severe heart conditions, chronic kidney disease, the obese, or people with weak immune system.
The patients in the Merck study and the patients in Pfizer study were drastically different. Merck gave the drug to people who were more than twice as likely to end up in the hospital. Pfizer gave their drug to a healthier population of patients, and, spoiler alert, saw less of them be hospitalized.
Merck’s control arm was hospitalized at 14.1%
Pfizer’s control arm was hospitalized at 7%.
What this means is the real-world efficacy for the Merck drug and the Pfizer drug could be quite similar. In the real world you can’t cherry pick your patients. Covid-19 rips through everyone.
Also: Merck gave their drug to unvaccinated people, while Pfizer hasn’t said whether their participants were vaccinated or not.
All the headlines are saying “Game changer” or “The beginning of the end of the pandemic.” The reality is, there is still quite a bit of room for improvement. Pfizer’s results might have been near the same, or even worse than Merck’s had they run their trial on actual high-risk patients. If both drugs are approved, a study will be run comparing them against each other. It might even show the Merck drug to be superior.
If Pfizer’s drug trial was run with “high-risk patients” then Merck’s drug trial was run with “extreme risk” patients. Their results shouldn’t be compared as simply as 89% vs 50%. You wouldn’t compare the effectiveness of cancer drugs in patients with stage 2 against a trial run on stage 3 patients, would you?
Of course not.
This means there is still room for improvement in the oral Covid-19 treatment space. Pfizer might have shot themselves in the foot by running a trial against a relatively healthier population. This is bad science and gives vulnerable people false hope.
If you’re at extreme risk of being hospitalized by Covid-19 then it’s unlikely that if you take the Pfizer pill your chance of ending up in the hospital is reduced by 89%. It’s probably a lot lower. Maybe as low as 40-50%. But we won’t know until the drug is out in circulation.
If the Pfizer drug is quickly approved it will set a bad precedent for therapeutics for Covid-19. It will open the floodgates to low-grade trials and outright scams. Companies might even run trials on supremely healthy people. While this won’t fool the FDA, it will lead to pump-and-dump scams.
You can read the article at this link. I have posted most of it below.
https://www.griproom.com/fun/pfizers-covid-pi...yre-saying
After stating on November 2nd that trial results for their Covid-19 pill might not be out until 2022, Pfizer released results this morning (three days later) touting an 89% reduction in hospitalization.
Merck’s Covid-19 pill (50% reduction in hospitalization with possibly mutagenic side-effects) was an obvious cash grab. Their sales team was scrambling to dump the product and sign deals before better oral treatments were announced. And they would have gotten away with it to, if it wasn’t for that meddling Pfizer. Atea/Roche’s drug flopped in trials, and Pfizer said their data would be delayed by months. This would have given Merck a tiny window to unload their drug. Just yesterday the UK approved molnupiravir, although they’re now probably regretting it.
89% vs 50% sounds like it’s a lot better, right? But here’s the thing. Merck’s trial was a lot different. Pfizer had 45% US patients. Merck only 7%. (We can expect the healthcare given to US patients in a big pharma study to be better than the healthcare given in India.) While not a deal-breaker, this next bit of data is.
Covid-19 disproportionately affects certain groups. Like people with diabetes, hypertension, asthma, chronic lung disease, severe heart conditions, chronic kidney disease, the obese, or people with weak immune system.
The patients in the Merck study and the patients in Pfizer study were drastically different. Merck gave the drug to people who were more than twice as likely to end up in the hospital. Pfizer gave their drug to a healthier population of patients, and, spoiler alert, saw less of them be hospitalized.
Merck’s control arm was hospitalized at 14.1%
Pfizer’s control arm was hospitalized at 7%.
What this means is the real-world efficacy for the Merck drug and the Pfizer drug could be quite similar. In the real world you can’t cherry pick your patients. Covid-19 rips through everyone.
Also: Merck gave their drug to unvaccinated people, while Pfizer hasn’t said whether their participants were vaccinated or not.
All the headlines are saying “Game changer” or “The beginning of the end of the pandemic.” The reality is, there is still quite a bit of room for improvement. Pfizer’s results might have been near the same, or even worse than Merck’s had they run their trial on actual high-risk patients. If both drugs are approved, a study will be run comparing them against each other. It might even show the Merck drug to be superior.
If Pfizer’s drug trial was run with “high-risk patients” then Merck’s drug trial was run with “extreme risk” patients. Their results shouldn’t be compared as simply as 89% vs 50%. You wouldn’t compare the effectiveness of cancer drugs in patients with stage 2 against a trial run on stage 3 patients, would you?
Of course not.
This means there is still room for improvement in the oral Covid-19 treatment space. Pfizer might have shot themselves in the foot by running a trial against a relatively healthier population. This is bad science and gives vulnerable people false hope.
If you’re at extreme risk of being hospitalized by Covid-19 then it’s unlikely that if you take the Pfizer pill your chance of ending up in the hospital is reduced by 89%. It’s probably a lot lower. Maybe as low as 40-50%. But we won’t know until the drug is out in circulation.
If the Pfizer drug is quickly approved it will set a bad precedent for therapeutics for Covid-19. It will open the floodgates to low-grade trials and outright scams. Companies might even run trials on supremely healthy people. While this won’t fool the FDA, it will lead to pump-and-dump scams.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼